Zoetis Inc.
ZTSNYSELatest results at a glance
Insights from the latest company results and reports · filed 6 Aug 2026
Q2 Revenue Flat, EPS Beats
Zoetis reported second-quarter 2026 revenue of $2.5 billion, flat year-over-year, and net income of $691 million, or $1.65 per diluted share. The reported diluted EPS of $1.87 exceeded the same-quarter consensus estimate of $1.85.
U.S. Segment Declines
U.S. segment revenue totaled $1.3 billion, decreasing 7% on both a reported and organic operational basis. Companion animal product sales fell 11%.
International Segment Grows
International segment revenue was $1.2 billion, increasing 8% on a reported basis and 6% on an organic operational basis. Growth was led by the parasiticides portfolio, including Simparica Trio, and contributions from companion animal diagnostics and osteoarthritis pain products.
Full-Year Guidance Revised
Guidance for adjusted diluted EPS was revised to $6.15 to $6.25.
Margin Trends Stable
Adjusted cost of sales as a percentage of revenue was approximately 29.0%, up from approximately 28.5% in the prior-year period.
Company research evidence
Checked financial measurements with the values, reporting periods and measurement basis shown together. This evidence is available independently of the AI report.
Loading evidence…
Deep Dive Research
Source-linked company research for ZTS
Revenue segmentation
Loading segment disclosures…